Table 4.

Prophylaxis characteristics.

	Patients without joint involvement (n = 46)	Patients with joint involvement (n = 14)	P value
Median (IQR) duration of prophylaxis, months	96 (65-149)	152 (102-203)	.042
Median (IQR) FVIII trough levels, UI/dL	0.9 (0.4-1.8)	2.4 (0.9-4.7)	.026
Total number of FVIII assays analyzed (n)	362	107
Median (IQR) dosage, IU/kg/year	6080 (5,090-7,561)	6622 (6,153-10,410)	.052
Adherence, %	96 (87-102)	88 (80-101)	.167
Standard half-life FVIII products
•Plasma–derived FVIII concentrates, %	-	28.6
•Recombinant FVIII concentrates, %	100	71.4
Switch to extended half-life FVIII products, (n), %	14 (30.4)	1 (7.1)

FVIII, factor VIII.